Clinical experience with spiramycin in bisphosphonate-associated osteonecrosis of the jaw

International Journal of Immunopathology and Pharmacology
G GaspariniS Pelo

Abstract

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) consists of an exposure of the jaw bone that persists for over 8 weeks in patients with positive history for bisphosphonates. Symptomatology is characterized by dull and ceaseless pain, and in advanced stages, the exposure of necrotic bone is evident, which is frequently associated with purulent secretions and faetor oris. Despite many different studies on BRONJ, there are no general guidelines to treat this disease. In this work, the authors present their experience in BRONJ conservative therapy with spiramycin by comparing the results achieved with amoxicillin and clavulanic acid. From January 1, 2008 to June 30, 2008, our department received 25 patients who were affected by osteonecrosis secondary to bisphosphonates. Thirteen had taken bisphosphonates for osteoporosis and 12 for malignancies. We divided the 25 patients into two groups: those who had not received any treatment and those who had received treatment. The first group of 13 patients had been treated only with spiramycin (S). The results from this group were only evaluated to test the efficacy of spiramycin and were not considered in the study. The second group of 12 patients had not undergone any previous tre...Continue Reading

References

Sep 11, 2003·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Robert E Marx
Oct 4, 2007·The Journal of Craniofacial Surgery·Gianluigi LongobardiSandro Pelo
Dec 3, 2008·The Journal of the American Dental Association·Beatrice J EdwardsUNKNOWN American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw
Oct 3, 2009·The Journal of the American Dental Association·Parish P SedghizadehJ William Costerton
Dec 8, 2009·Australian Endodontic Journal : the Journal of the Australian Society of Endodontology Inc·Salvatore L RuggieroUNKNOWN Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons
Dec 18, 2009·International Journal of Oral and Maxillofacial Surgery·R A Williamson
Jan 16, 2010·Postgraduate Medical Journal·P RyanL F A Stassen
Feb 23, 2010·The Journal of Clinical Endocrinology and Metabolism·Nelson B Watts, Dima L Diab

❮ Previous
Next ❯

Citations

Feb 27, 2016·The Cochrane Database of Systematic Reviews·Victoria RollasonNicole B Vogt-Ferrier
Oct 1, 2011·International Journal of Immunopathology and Pharmacology·E CenniN Baldini
Dec 1, 2010·Archives of Pharmacal Research·Hyoung Jin KimSoon Ha Kim
Jul 23, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Noam YaromDeborah P Saunders

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.